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Abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) can subvert early 
innate immunity, which leads to ineffective antimicrobial responses. Overcoming immune 
subversion is critical for developing vaccines and other measures to control this devastating 
swine virus. The overall goal of this work was to enhance innate and adaptive immunity 
following vaccination through the expression of interferon (IFN) genes by the PRRSV 
genome. We have constructed a series of recombinant PRRS viruses using an infectious 
PRRSV cDNA clone (pCMV-P129). Coding regions of exogenous genes, which included 
Renilla luciferase (Rluc), green and red fluorescent proteins (GFP and DsRed, respectively) 
and several interferons (IFNs), were constructed and expressed through a unique 
subgenomic mRNA placed between ORF1b and ORF2 of the PRRSV infectious clone. The 
constructs, which expressed Rluc, GFP, DsRed, efficiently produced progeny viruses and 
mimicked the parental virus in both MARC-145 cells and porcine macrophages. In 
contrast, replication of IFN-expressing viruses was attenuated, similar to the level of 
replication observed after the addition of exogenous IFN. Furthermore, the IFN expressing 
viruses inhibited the replication of a second PRRS virus co-transfected or co-infected. 
Inhibition by the different IFN subtypes corresponded to their anti-PRRSV activity, 
i.e., IFNω5  IFNα1 > IFN-β > IFNδ3. In summary, the indicator-expressing viruses 
OPEN ACCESS
Viruses 2012, 4  
 
 
103
provided an efficient means for real-time monitoring of viral replication thus allowing 
high-throughput elucidation of the role of host factors in PRRSV infection. This was 
shown when they were used to clearly demonstrate the involvement of tumor susceptibility 
gene 101 (TSG101) in the early stage of PRRSV infection. In addition, replication-competent 
IFN-expressing viruses may be good candidates for development of modified live virus 
(MLV) vaccines, which are capable of reversing subverted innate immune responses and 
may induce more effective adaptive immunity against PRRSV infection. 
Keywords: porcine arterivirus; virus cDNA infectious clone; indicator proteins; type I 
interferon; host factors; tumor susceptibility gene 101 
 
1. Introduction  
More than 20 years after initial reports [1–3], porcine reproductive and respiratory syndrome virus 
(PRRSV) continues to be a global swine industry problem with losses in the U.S. approaching 
$6 billion over the last decade [4]. Belonging to the arteriviridae family in the order nidovirales, 
PRRSV is an enveloped RNA virus containing a single positive-strand RNA genome. The 15 kb viral 
RNA genome consists of seven open reading frames (ORF1-7). ORF1 comprises about 80% of the 
genome and encodes proteins with protease, replicase and regulatory functions. The smaller 
overlapping ORF2-7 encode five minor (GP2a, GP3, GP4, 5a and E proteins) and three major (GP5, M 
and N proteins) structural proteins [5–7]. Several studies have shown that PRRSV possesses the 
capacity to subvert early innate immune responses in pigs by suppressing the production of antiviral 
cytokines [8–15], which also contributes to ineffective B- and T-cell responses [16–19]. Superimposed 
on this suppressive activity is a high viral mutation rate, which has made the development of vaccines 
challenging [20]. Modified live vaccines (MLV) used for control of PRRSV in the U.S. are based on 
only two virus isolates [20,21]. Although MLV protect against some homologous field strains, their 
efficacy is not satisfactory due to failure to protect against infections of heterologous strains, as well as 
the potential risk for reversion to virulence [20,21]. To develop successful vaccines against PRRSV 
infections, particularly those by heterologous strains, it is necessary to develop novel vector systems 
and to extensively categorize host factors critical in the virus-host interaction.  
Several viral vectors, including those based on pseudorabies virus, poxvirus, adenovirus 
and transmissible gastroenteritis coronavirus (TGEV) have been used to express PRRSV structural 
proteins [22] or host immune factors [23–25] for developing anti-PRRSV immunity. For example, 
humoral immunity against PRRSV GP5 protein was detected in pigs immunized with fowlpoxvirus-
coexpressing PRRSV GP5/GP3 and porcine IL-18 [23], and in mice immunized with adenovirus-
expressing GP5/GP3 fused with swine granulocyte-macrophage colony stimulating factor (GM-CSF) [25]. 
In this context, we and others have proposed to use PRRSV infectious cDNA clones [26,27] or virus 
replicons [28] as vectors for the expression of immune effectors that potentiate innate and adaptive 
immunity against a broad range of PRRSV isolates. Here we show that PRRSV infectious clones are 
effective vector systems to express exogenous antigens and host immune effectors. Specifically, we 
have constructed serial replication-competent viruses from a PRRSV infectious clone-based vector 
Viruses 2012, 4  
 
 
104
expressing indicator proteins and porcine type I interferons (IFNs). The indicator protein-expressing 
PRRS viruses efficiently produce progeny viruses and provide an efficient means for real-time 
monitoring of viral replication, thus allowing high-throughput elucidation of the role of host factors in 
PRRSV infection. In addition, the replication of some IFN-incorporated viruses is associated with the 
expression of active IFN peptides, which are capable of counteracting the subverted innate immune 
response and with potential to induce more effective adaptive immunity against PRRSV infection. 
2. Results and Discussion  
2.1. Producing Replication-Competent PRRSV Coexpressing Indicator Proteins  
To investigate the potential of infectious PRRSV cDNA clones as a platform for gene manipulation 
[29,30], we first engineered an established infectious clone to express several indicator proteins 
including Renilla luciferase (Rluc), and green and red fluorescent proteins (GFP and DsRed, 
respectively). Coding regions of the indicator proteins were constructed in the junction regions 
surrounding ORF1b/ORF2a through introduced restrictive digestion sites as described [29,30] 
(Figure 1A). The construct was designed to express the recombinant protein gene through the creation 
of an additional subgenomic mRNA. Plasmids of selected authentic clones were transfected into 
MARC-145 cells for the production of progeny viruses. As shown in Figure 1, infectious clones 
efficiently produced progeny viruses with successful expression of indictor proteins (Figure 1B). 
Replication rates of these engineered viruses were similar to their parental virus as judged by 
monitoring ratios of virus-positive cells; and they produced comparable infectious virons shown by 
similar viral titers (Figure 1C). Further experiments with GFP-PRRSV have shown their similar 
infectivity as a parental strain in porcine alveolar macrophages (PAMs) as well as monocyte-derived 
dendritic cells (mDCs) (Figure 1B and data not shown). The indicator-expressing viruses provide an 
efficient means for real-time monitoring of viral replication. Whereas GFP- and DsRed-PRRSV 
facilitated detection of fluorescent proteins after 16 h, the Rluc-PRRSV was useful for measuring Rluc 
activity from 5–20 h.  
These viruses allowed us to efficiently elucidate the role of some host factors in PRRSV infection. 
Several infectious cDNA clones have been generated from field PRRSV strains [31–37], which 
provide efficient means for molecular manipulation of PRRSV genome and evaluation of molecular 
evolution of this RNA virus with a high mutation rate. The vector cassette used in this study was 
generated from an infectious clone of North American PRRSV strain P129 with two unique restriction 
sites and a copy of the transcription regulatory sequence of ORF6 (TRS6) inserted between ORFs 1b 
and 2a [26,27,29,30]. In addition to GFP, which was introduced in PRRSV infectious clones in several 
previous studies [26,27,29,31], two other indicator proteins of DsRed and Rluc were introduced in the 
PRRSV cDNA clone in this study. The construction of DsRed and particularly Rluc into the PRRSV 
cDNA clone was intended to produce laboratory viruses that mimic their parental PRRSV with similar 
replication kinetics but are easily detected and quantified during the early phase of virus 
infection/replication. As shown in both MARC-145 cells and PAMs, all GFP, DsRed and Rluc 
expressing progeny viruses had similar replication kinetics as their parental PRRSV. For detection, the 
red fluorescence of DsRed labeling not only provided a counterstaining choice but also was more 
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sensitive for microscopic observation in real-time rather than traditional immunostaining procedures in 
fixed cells (Rural Technologies, Brookings, SD, USA). In contrast to GFP and DsRed viruses, which 
were generally detectable after 12 h in infected cells using microscopy, the Rluc PRRSV in 
conjunction with an EnduRen™ in vivo substrate (Promega, Madison, WI) facilitated real-time 
detection of the virus replication as early as 5 h post infection in cells. This Rluc expressing PRRSV 
thus provides an efficient means for genome-wide examination of host factors involved in the early 
stages of virus infection [38,39]. However, our attempts to clone the firefly luciferase gene (~1.6 kb) 
into the same PRRSV cDNA vector were unsuccessful, suggesting that the PRRSV clone vector has a 
limited capacity for incorporation of exogenous genes at about 2 kb.  
Figure 1. Infectious Porcine reproductive and respiratory syndrome virus (PRRSV) cDNA 
clone as a vector for bioengineered expression of indicator proteins. (A) Schematic of an 
infectious PRRSV cDNA clone, pCMV-P129-GFP, as an expression cassette [29].  
(B) Co-infection of GFP- and DsRed-viruses (2nd passage of the rescued viruses, P2) in 
MARC-145 cells. Viruses were demonstrated by fluorescence of the indicator proteins. 
(C) Infection of porcine myeloid-derived dendritic cells with the Renilla luciferase (Rluc) 
(P6). Viruses were demonstrated by immunostaining PRRSV N protein indirectly labeled 
with TRITC. (D) Propagation dynamics of engineered viruses, values in parentheses are 
titers (logTCID50/mL) of P2 viruses. 
2.2. Indicator Proteins Expressing PRRS Viruses Reveal the Involvement of Tumor Susceptibility 
Gene 101 (TSG101) in the Early Stage of PRRSV Infection  
TSG101 is a housekeeping protein and has been implicated in a number of cellular functions, 
including mitotic spindle formation, genome stability and endosomal sorting [40]. Essential in 
endosomal sorting, TSG101 interacts directly with ubiquitinated proteins and internalizes them into the 
multivesicular body pathway for degradation. During replication, viruses require a retrograde 
movement from the cell interior to the outer membrane [40]. A number of reports have shown that 
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TSG101 is involved in the virus fusion/budding process from the cellular membrane. These viruses 
include human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [40–42]. Recently, a 
tentative TSG101-targeting peptide, FGI-104, was shown to have a broad-spectrum ability to inhibit 
infections by several viruses including HIV, HCV and PRRSV [43]. However, there is no direct 
mechanistic evidence that has demonstrated the involvement of TSG101 in the control of PRRSV 
replication. To study this possibility, we produced MARC-145 cell lines with targeted suppression of 
endogenous TSG101 expression. MARC-145 cells were transfected with a pGFP-V-RS vector 
expressing a 29 nt shRNA (OriGene, Rockville, MD, USA) against a conserved region of TSG101. 
Two puromycin-resistant colonies showing significant suppression of TSG101 at both RNA and 
protein levels, were selected. As shown in Figure 2A, cells from colony 1 had less than 10% 
endogenous expression of tsg101 RNA, and those from colony 9 about 20% of endogenous expression 
of tsg101 RNA, as well as 70–80% reduction in TSG101 protein. We then compared PRRSV 
replication in these TSG101-suppressed cells with control MARC-145 cells or cells transfected with 
scrambled shRNA constructs. Using either GFP- or DsRed-expressing PRRSV, the retarded replication 
of viruses in TSG101-suppressed cells was demonstrated between 12 and 48 h after infection 
(Figure 2B,C). However, by 72 h, viral replication among TSG101-suppressed and control cells was 
not significantly different (Figure 2D). The return of PRRSV replication in TSG101-suppressed cells 
might result from virus-stimulated expression of TSG101 and/or incomplete suppression. The earlier 
and more quantitative comparison of PRRSV replication among TSG101-suppressed and control cells 
was conducted with the Rluc-expressing PRRSV. Significantly retarded viral replication was detected 
as early as 5 h post Rluc-PRRSV infection with the in vivo Rluc substrate. The difference in PRRSV 
replication was quantitatively correlated to the TSG101 levels in different group of cells (Figure 2A 
and 2E), and could be monitored until 20 h post infection when the substrate was limited. Notably, the 
replication retardation of indicator protein-expressing viruses in TSG101-silent cells was mostly due to 
TSG101 suppression because these bioengineered viruses have similar replication kinetics as their 
parental viruses in normal cells (Figure 1). Using the kinetics (i.e., 12–20 h post infection) defined by 
the indicator protein-expressing viruses, we reproducibly detected retarded replication rates of wild-
type PRRS viruses in TSG101 suppressed cells (data no shown). To further test the role of TSG101 in 
PRRSV infection in porcine cells or pigs, we have characterized the porcine TSG101 cDNA sequence 
(GenBankTM accession numbers JN882576). The full-length porcine TSG101 cDNA is 1580 bp 
encoding a precursor protein of 391 residues. TSG101 genes are conserved with most mammalian 
homologs sharing >94% identity at both RNA and protein levels. The shRNA template sequence we 
used for loss-of-function studies in MARC-145 cells is identical among human, monkey and porcine 
TSG101 cDNA. Transient transformation of the shRNA into porcine mDCs similarly suppressed GFP, 
DsRed- and Rluc-expressing PRRSV until 48 h post infection (data not shown).  
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Figure 2. Indicator protein-expressing PRRS viruses are effective tools for deciphering the 
role of host factors in PRRSV infection. (A) Producing cell clones of MARC-145 cells 
with the suppression of a cellular protein of tumor susceptibility gene 101 (TSG101).  
(B1–D4) Retarded replication of PRRSV in TSG101-suppressed cells (B1–D2) as shown 
with DsRed-PRRSV in comparison to control cells (B3–D4). Merged: merged with 
fluorescent and bright field. (E) Real-time monitoring retarded replication of PRRSV in 
TSG101-suppressed cells with the luciferase activity of the recombinant Rluc-PRRSV. The 
significant suppression of PRRSV replication in early phase but not latter phase of 
infection is clearly shown with the real-time measure using the indicator protein-expressing 
viruses, which is critical for detecting the window of a host factor involved in PRRSV 
infection. * p < 0.05, n = 3, to normal or scramble shRNA transfected cells. 
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2.3. Replication-Competent PRRSV Coexpressing Type I Interferons 
To determine the potential of host factors as a means of counteracting viral immunomodulating 
activity and stimulating effective antiviral immunity [44], we bioengineered the infectious clones to 
express a variety of type I IFNs, which were selected because of their well-documented role in PRRSV 
infections and activity in mediation of antiviral immunity [9,15,45–47]. In addition, the suppression of 
type I IFN expression by PRRSV infection has been well documented [15]. Shown in Figure 3 are data 
from the infectious clone expressing four type I IFNs (IFNα1, IFNβ, IFNδ3 and IFNω5). At 4 d post 
transfection with equivalent cDNA clones, virus-positive cells were detected in cells transfected with 
all four infectious clones but with different densities. Where IFNδ3-PRRSV propagated similarly as 
the control GFP-virus, the replication rates of IFN-β-, IFNα1- and IFNω5-viruses were attenuated by 
approximately 70% (β-type) or 90% (α1- & ω5-types) (Figure 3A–H). Attenuation of IFN-expressing 
viruses could be caused by viral genome alteration or more likely by the replication-associated 
expression of active IFN peptides, which was consistent with the anti-PRRSV activity of these IFN 
subtypes [15] (Figure 3C). In contrast, IFNδ3- and GFP-type viruses replicated well. To confirm these 
findings, we counterstained IFNα1-virus infected cells with antibodies against porcine IFNα (R&D, 
Minneapolis, MN, USA) and PRRSV nucleocapsid (N) protein (Figure 4A–D). Co-localization of 
IFNα- and PRRSV-labeling (Figure 4C) indicated that IFN polypeptides were expressed by the 
engineered viruses during infection. Furthermore, the IFN expressing viruses inhibited the replication 
of a second PRRS virus co-transfected or co-infected; and again, the intensity of the inhibition was 
consistent with the anti-PRRSV activity of these IFN subtypes, i.e., IFNω5IFNα1>IFN-β>IFNδ3 
(Figure 4E). However, because the expression of IFN inhibits virus replication [22,44], engineered 
viruses with the most active IFN subtypes against PRRSV may not be good candidates for a modified 
live virus (MLV) vaccine. This limitation would prevent the preparation of a high titer virus as a 
vaccine. Several measures may be used to overcome these limitations, such as incorporating 
IFN subtypes that do not inhibit replication of a MLV strain but may up-regulate B- and T-cell 
responses [44], or controlled expression/activation of the incorporated IFN peptides within certain 
temporal windows or cell types. Pigs have at least 35 functional type I IFN genes with diverse antiviral 
or immunoregulatory activity [47], which provides several candidates for balancing antiviral and 
immunoregulatory activity to optimize the replication-competent recombinant viruses. Type I IFNs 
mediate antiviral responses through induction of IFN stimulated genes, such as MxA and RNase L. 
Direct incorporation of some ISGs (or their functional domains) into the PRRSV infectious clone 
provides an attractive alternative given that PRRSV-specific ISGs have been identified [15]. In 
addition, incorporating an exogenous gene tag (a compliance marker) at the vector backbone of a MLV 
will also allow differentiation of vaccinated from non-vaccinated animals [27].  
As for the stability of the bioengineered viruses, we passed viruses through MARC-145 cells and 
PAMs for 5–6 generations. Authentic progeny viruses were rescued after three generations, but viruses 
with a titer higher than 103 were only rescued with the indicator protein expressing group and the one 
expressing IFNδ3. DsRed- and IFNδ3-expressing viruses remained stable for 6 generations (Data 
not shown).  
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Figure 3. Infectious PRRSV cDNA clone as a vector for bioengineered expression of 
immune effectors. (A–E) MARC-145 cells were transfected with equal amounts of 
indicated infectious constructs, and immunostained for PRRSV at 4 d post-transfection 
with antibody against the PRRSV N protein indirectly labeled with TRITC; 
(F) GFP-PRRSV immunostained as in E1 but shown here as green fluorescence of GFP; 
(G) Merged (E1) and (F) to show specificity of the immunostaining procedure; 
(H) Propagation rate of IFN-engineered viruses, values in parentheses are titers 
(logTCID50/mL) of P2 viruses. * p < 0.05, n = 3, to IFNα1-PRRSV.  
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Figure 4. Interferon (IFN)-engineered viruses express active IFN peptides and induce  
anti-PRRSV activity in MARC-145 cells. (A–D) Counterstained PRRSV and IFN-α1 in 
IFN-α1-PRRSV transfected cells at 4 d post transfection; (E) IFN-engineered PRRSV 
showed suppression of co-transfected (GFP-PRRSV) or co-infected (SDSU28983, infected 
at 3 d post transfection) viruses. Total virus-infected cells were examined at 5 d post 
transfection to calculate suppression rate in comparison to controls. ** p < 0.01, * p < 0.05, 
n = 3, to cells only transfected with GFP-PRRSV. 
 
3. Experimental Section  
Viruses and cells: All virus and animal procedures were approved by the Kansas State University 
Biosafety and Institutional Animal Care and Use committees. The wild type strains of PRRSV used 
here were two North American PRRSV strains: NVSL97-7895 and SDSU28983 [26,27]. The 
expression cassette was created by insertion of two unique restriction sites and a copy of the 
transcription regulatory sequence of ORF6 (TRS6) between ORFs 1b and 2a in the infectious cDNA 
clone of pCMV-P129 (Figure 1A) [29,30] (gift from Dr. Jay G. Calvert, Pfizer Animal Health, 
Kalamazoo, MI, USA). All bioengineered viruses originated from the backbone of pCMV-P129 with 
incorporation of an exogenous gene between the two cloning sites. All PRRSV strains were propagated 
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in a simian kidney cell line (MARC-145) or porcine alveolar macrophages (PAMs). MARC-145 
cells were maintained in minimum essential medium (MEM) with 8% fetal bovine serum (FBS) and 
1× penicillin/streptomycin and fungizone (Invitrogen, Grand Island, NY, USA) PAMs were obtained 
from lungs of 4- to 6-week-old pigs by lung lavage with PBS and cryopreserved in liquid nitrogen until 
use. In use, PAMs were plated in RPMI medium with 10% FBS plus 1X penicillin/streptomycin and 
fungizone. After 2 d, cells were infected with the virus [47]. Monocyte-origin dendritic cells (mDCs) 
were induced from porcine peripheral blood mononuclear cells (PBMCs) and infected with PRRS 
viruses as described in Loving et al. [48].  
Production and titration of recombinant PRRS viruses with expression of exogenous genes: In brief, 
two restriction enzyme digestion sites (Afl II and Mlu I) were introduced into 5'- and 3'-ends of the 
coding regions, which were amplified from authentic cDNA clones using a high-fidelity PCR [15,47]. 
The cloning primers used for this study are listed in the Supplemental Table 1. The amplified coding 
regions were purified and cloned into the expression cassette. MARC-145 cells were transfected with 
authentic plasmids purified from E. coli clones for examination of the production of progeny viruses 
and expression of indicator proteins or IFNs. Transfection of MARC-145 in 24-well plates was 
performed with 2 μg of plasmid DNA using Lipofectamine™ 2000 (Invitrogen). Subsequent virus 
yields were measured by end-point titration of culture media on MARC-145 cells and PAMs. Serial 
10-fold dilutions of virus were placed in 96-well tissue culture plates containing confluent MARC-145 
cells or PAMs. Cells were fixed in 4% formaldehyde in PBS and the virus was detected by staining for 
the presence of nucleocapsid antigen using a mAb (SDOW-17, Rural Technologies, Brookings, SD, 
USA) labeled with TRITC-conjugated secondary antibodies. In addition, the recombinant viruses 
could be distinctly detected by the expression of fluorescent proteins. Results were reported as 
logTCID50/mL [15,47]. The replication of Rluc-expressing PRRSV was monitored with the addition of an 
in vivo Renilla luciferase substrate (Promega, Madison, WI, USA) at 60 μM in cell culture medium and 
measured the luminescence after 2 h [49].  
Determination of growth kinetics and stability of the recombinant viruses in cells: Culture 
supernatants from cells transfected with infectious clones were harvested at 5 d post-transfection and 
designated ‘passage (P) 1’. The P1 virus was used to inoculate fresh MARC-145 cells to collect P2 
then P3 at an interval of 4–5 d between successive passages. Each passage virus was titrated, aliquoted 
and stored at −80 °C until use. Growth curves of the rescued viruses were evaluated by inoculating 
MARC-145 cells with P3 viruses at a MOI of 0.1. Aliquots of the supernatants of infected cells were 
collected at points with 10 h intervals until 100 h and the virus was titrated by determining logTCID50/mL 
to monitor growth kinetics [26]. To determine the stability of the recombinant virus, the rescued P1 
virus was passaged on MARC-145 and PAM cells until P6. Expression of indicator proteins and IFN 
along with virus replication was detected by RT-PCR, western blotting and immunofluorescence as 
described above [15,47].  
Producing MARC-145 cell lines with shRNA-mediated silencing of the Tsg101 gene: Three g of 
pGFP-V-RS vector expressing a scrambled shRNA or a 29 nt shRNA (OriGene, Rockville, MD, USA) 
against a conservative region between human and simian TSG101 cDNA, was used to transfect 
MARC-145 cells growing in 6-well culture plates. Transfected cells were selected with 0.8 µg/mL of 
puromycin (Invitrogen) to obtain individual colonies. Approximately 30 puromycin-resistant colonies 
were picked and two of them showing significant suppression of TSG101 at both RNA and protein 
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levels were subcultured for loss-of-function studies of the role of TSG101 in PRRSV infection. 
Primers used for RT-PCR detection of tsg101 were generated against consensus sequence of monkey, 
human and porcine tsg101 cDNAs (GenBankTM accession numbers, NM_001195481, NM_006292 
and JN882576, respectively), which allowed us to detect both monkey and porcine tsg101 with the 
same pair of primers. The primers were 5′-ATACCCTCCCAATCCCAGTGGTTA-3′ (sense) and 
5′-ATCCATYTCCTCCTTCATCCGCCA-3′ (antisense, Y = C or T). Anti-TSG101 monoclonal antibody 
was purchased from Sigma-Aldrich (St. Louis, MO, USA). The involvement of TSG101 in PRRSV 
infection was evaluated by comparing the replication kinetics of PRRS viruses between cells with or 
without TSG101-suppression [47].  
Data analyses: Virus titrations were done with at least three repeats to report logTCID50/mL. Relative 
gene-expression data of real-time PCR was normalized against Ct values of the housekeeping gene 
(GAPDH) and the relative expression index (2−ΔΔCt) was determined in comparison to the base levels 
of control samples. Growth curves were generated with Sigmaplot 11.0 (Systat, San Jose, CA, USA) 
and the densitometry analysis of images were done by using AlphaEase FC Software (Alpha Inotech, 
Santa Clara, CA, USA) as described [47,50]. 
4. Conclusions 
The PRRSV cDNA infectious clone, pCMV-129, has vector capacity to express exogenous genes of 
less than 2 kb, which allows reconstruction of the virus for bioengineering manipulation [29,30].  
Recombinant PRRS viruses expressing several indicator proteins have replication and infection 
dynamics similar to the parental strain in both MARC-145 and porcine cells. Therefore, they may be 
used to decipher the role of host factors in PRRSV infection [38,39]. Using several indicator 
protein-expressing viruses, in particular the Rluc-expressing PRRSV, we showed that TSG101 was 
significantly involved in PRRSV infection at the early phase of the infection. 
Recombinant PRRS viruses expressing antiviral cytokines produce active cytokines in the infected 
cells and alter the replication of co-infected PRRSV. These constructs may be candidates for modified 
live virus vaccines, which could ameliorate subverted innate immune responses and potentially 
enhance adaptive immunity against PRRSV infection. 
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